Eli Lilly’s tirzepatide, already approved in type 2 diabetes and carrying high expectations in obesity, could break pharma sales records, an analyst team at UBS says. The also touted the potential for Lilly’s Alzheimer’s candidate donanemab. Six months after the FDA lifted a clinical hold, Pfizer is gearing up to resume dosing in a phase 3 hemophilia A gene therapy trial. Amid Pfizer's pause, rival BioMarin has worked to get its rival back on track. In a new poll, physicians report an increase in emergency department violence. That’s leading to burnout for healthcare providers and hurting patient care, they added. - Eric Sagonowsky | 